TexRAD analyses the textures in radiological scans to assist clinicians in assessing the prognosis of patients with cancer. TexRAD is being applied in a wide range of studies including colorectal, breast, lung, prostrate, oesophageal, head and neck, and renal cancers.Learn more about the software
Papers and Presentations
TexRAD is actively engaged with leading researchers around the world and has been the subject of many papers and conferences posters and presentations.Look at our research base
What our clients say
“TexRAD assists clinical decision-making by predicting the risk of disease and assessing the prognosis for cancer patients”
Professor Ken Miles, Consultant RadiologistSee our research customers
TexRAD was launched with a vision to be able to equip health care providers with accurate and efficient technology that enhanced overall patient care and quality of service using heterogeneity and texture analysis.More about our company
TexRAD are Runners Up in MediLink National Awards Published on April 4, 2014 which followed from the success of winning the SEHTA regional award for Innovation.Read more ...